| 1 | Can we predict the risk of venous thromboembolism in patients with Cushing’s syndrome: a nationwide cohort analysis | 2.6 | 8 | Citations (PDF) |
| 2 | Cushing’s syndrome related to higher rates and earlier onset of cataract: A nationwide retrospective cohort study | 1.8 | 1 | Citations (PDF) |
| 3 | Osilodrostat improves blood pressure and glycemic control in patients with Cushing’s disease: a pooled analysis of LINC 3 and LINC 4 studies | 2.6 | 19 | Citations (PDF) |
| 4 | Leukocytosis in Cushing’s syndrome persists post-surgical remission and could predict a lower remission prognosis in patients with Cushing’s disease | 2.8 | 4 | Citations (PDF) |
| 5 | Delphi panel consensus on recommendations for thromboprophylaxis of venous thromboembolism in endogenous Cushing's syndrome: a position statement | 4.0 | 17 | Citations (PDF) |
| 6 | Osilodrostat Treatment for Adrenal and Ectopic Cushing Syndrome: Integration of Clinical Studies With Case Presentations | 0.3 | 15 | Citations (PDF) |
| 7 | Impact of remission status in endogenous Cushing's syndrome on cancer incidence | 4.0 | 6 | Citations (PDF) |
| 8 | Cancer screening in patients with acromegaly: a plea for a personalized approach and international registries | 6.7 | 13 | Citations (PDF) |
| 9 | Osilodrostat Treatment of Cushing Syndrome in Real-World Clinical Practice: Findings From the ILLUSTRATE study | 0.3 | 14 | Citations (PDF) |
| 10 | Mortality in Cushing's syndrome: declining over 2 decades but remaining higher than the general population | 4.0 | 12 | Citations (PDF) |
| 11 | PANOMEN-3 grading score is reliable in predicting pituitary adenoma behavior and prognosis: a single center cohort study | 2.5 | 7 | Citations (PDF) |
| 12 | Predictors of cancer in patients with endogenous Cushing’s syndrome | 3.5 | 1 | Citations (PDF) |
| 13 | Weight gain reversibility and BMI following treatment for Cushing’s syndrome: long-term outcomes and potential predictors | 2.6 | 10 | Citations (PDF) |
| 14 | Prolactin-secreting adenomas: pathogenesis, diagnosis, and management | 21.7 | 28 | Citations (PDF) |
| 15 | Reply to ‘The shift of therapeutic strategy for prolactinomas: surgery as the first-line option’ | 31.8 | 1 | Citations (PDF) |
| 16 | Reply to ‘Tumour fibrosis in dopamine agonist-exposed prolactinomas is a diminishing concern’ | 31.8 | 1 | Citations (PDF) |
| 17 | Improvement in clinical features of hypercortisolism during osilodrostat treatment: findings from the Phase III LINC 3 trial in Cushing's disease | 2.8 | 12 | Citations (PDF) |
| 18 | Hypopituitarism and bone disease: pathophysiology, diagnosis and treatment outcomes | 2.6 | 10 | Citations (PDF) |
| 19 | Hypopituitarism | 62.1 | 100 | Citations (PDF) |
| 20 | Impact of etiology, sex, diabetes mellitus and remission status on erythrocytic profile in patients with cushing’s syndrome: a large population database study | 2.6 | 5 | Citations (PDF) |
| 21 | Medical treatment of functional pituitary adenomas, trials and tribulations | 2.5 | 9 | Citations (PDF) |
| 22 | Oral octreotide capsules for acromegaly treatment: application of clinical trial insights to real-world use | 2.9 | 9 | Citations (PDF) |
| 23 | Diabetes mellitus in patients with acromegaly: pathophysiology, clinical challenges and management | 31.8 | 49 | Citations (PDF) |
| 24 | The conundrum of differentiating Cushing’s syndrome from non-neoplastic hypercortisolism: a systematic review and meta-analysis | 2.6 | 12 | Citations (PDF) |
| 25 | Acromegaly and COVID-19, lessons, and new opportunities | 2.6 | 2 | Citations (PDF) |
| 26 | Conundrums of Diagnosis and Management of Cushing’s Syndrome in Pregnancy | 3.5 | 9 | Citations (PDF) |
| 27 | Endogenous Cushing's syndrome and cancer risk | 4.0 | 16 | Citations (PDF) |
| 28 | Improved Clinical Outcomes During Long-term Osilodrostat Treatment of Cushing Disease With Normalization of Late-night Salivary Cortisol and Urinary Free Cortisol | 0.3 | 20 | Citations (PDF) |
| 29 | Delayed cerebral ischemia associated with surgery for pituitary macroadenomas that express elevated levels of PACAP | 0.8 | 1 | Citations (PDF) |
| 30 | Dynamic Testing for Differential Diagnosis of ACTH-Dependent Cushing Syndrome: A Systematic Review and Meta-analysis | 4.0 | 44 | Citations (PDF) |
| 31 | Pituitary and SARS CoV-2: An unremitting conundrum | 5.1 | 27 | Citations (PDF) |
| 32 | Symptoms at presentation in conservatively managed patients with non-functioning pituitary adenomas | 1.8 | 5 | Citations (PDF) |
| 33 | Sellar Metastatic Neuroendocrine Carcinoma of Unknown Origin: A Case Report and Review of the Literature | 0.6 | 1 | Citations (PDF) |
| 34 | Treatment Patterns in Acromegaly: Analysis of Real-World US Insurance Claims from the MarketScan® Database | 0.0 | 0 | Citations (PDF) |
| 35 | MPOWERED Trial Open-Label Extension: Long-term Efficacy and Safety Data for Oral Octreotide Capsules in Acromegaly | 4.0 | 21 | Citations (PDF) |
| 36 | Cushing Syndrome | 16.5 | 235 | Citations (PDF) |
| 37 | An individualized approach to the management of Cushing disease | 31.8 | 70 | Citations (PDF) |
| 38 | Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement | 31.8 | 362 | Citations (PDF) |
| 39 | Treatment Patterns, Adherence, Persistence, and Health Care Resource Utilization in Acromegaly: A Real-World Analysis | 0.3 | 15 | Citations (PDF) |
| 40 | THU061 Treatment Patterns In Acromegaly: Analysis Of Real-World US Insurance Claims From The MarketScan® Database | 0.3 | 0 | Citations (PDF) |
| 41 | Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease | 3.8 | 21 | Citations (PDF) |
| 42 | Cushing's syndrome | 62.1 | 160 | Citations (PDF) |
| 43 | Hypophysitis, the Growing Spectrum of a Rare Pituitary Disease | 4.0 | 139 | Citations (PDF) |
| 44 | Nonfunctioning Pituitary Microadenomas: Should Imaging Interval be Extended? A Large Single-center Cohort Study | 4.0 | 24 | Citations (PDF) |
| 45 | Prevalence of comorbidities and concomitant medication use in acromegaly: analysis of real-world data from the United States | 2.6 | 35 | Citations (PDF) |
| 46 | Personalized Medical Treatment of Patients With Acromegaly: A Review | 3.3 | 29 | Citations (PDF) |
| 47 | Patient-reported outcomes in patients with acromegaly treated with pegvisomant in the ACROSTUDY extension: A real-world experience | 2.6 | 19 | Citations (PDF) |
| 48 | Response to Letter to the Editor From Asa and Mete: “Hypophysitis, the Growing Spectrum of a Rare Pituitary Disease” | 4.0 | 0 | Citations (PDF) |
| 49 | Perioperative Management of a Patient With Cushing Disease | 0.3 | 33 | Citations (PDF) |
| 50 | Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial | 21.7 | 50 | Citations (PDF) |
| 51 | Clinical Study and Systematic Review of Pituitary Microadenomas vs. Macroadenomas in Cushing’s Disease: Does Size Matter? | 2.5 | 12 | Citations (PDF) |
| 52 | Clinical Biology of the Pituitary Adenoma | 24.6 | 302 | Citations (PDF) |
| 53 | A systematic literature review to evaluate extended dosing intervals in the pharmacological management of acromegaly | 0.0 | 0 | Citations (PDF) |
| 54 | Adult Growth Hormone Deficiency: Diagnostic and Treatment Journeys From the Patients’ Perspective | 0.3 | 11 | Citations (PDF) |
| 55 | Change in androgens and adrenal hormones during long-term osilodrostat treatment in patients with Cushing's disease: Results from the Phase III, prospective LINC 3 study | 0.0 | 0 | Citations (PDF) |
| 56 | Impact of urinary and late-night salivary cortisol levels on clinical signs of hypercortisolism and quality of life in patients with Cushing's disease treated with osilodrostat | 0.0 | 0 | Citations (PDF) |
| 57 | Osilodrostat therapy improves physical manifestations of hypercortisolism in patients with cushing's disease: findings from the phase III LINC 3 study | 0.0 | 0 | Citations (PDF) |
| 58 | The MPOWERED Trial Comparing the Effectiveness, Safety, and Patient Experiences’ of Monthly Injections and Oral Medication Used to Treat Acromegaly | 0.9 | 0 | Citations (PDF) |
| 59 | Treatment of Cushing’s syndrome with osilodrostat: practical applications of recent studies with case examples | 2.6 | 47 | Citations (PDF) |
| 60 | Levoketoconazole in the treatment of patients with endogenous Cushing’s syndrome: a double-blind, placebo-controlled, randomized withdrawal study (LOGICS) | 2.6 | 43 | Citations (PDF) |
| 61 | Acromegaly: pathogenesis, diagnosis, and management | 21.7 | 266 | Citations (PDF) |
| 62 | Novel approaches for cushing’s medical management: Guidelines to clinical practice | 0.0 | 0 | Citations (PDF) |
| 63 | Long-term efficacy and safety of osilodrostat in Cushing’s disease: final results from a Phase II study with an optional extension phase (LINC 2) | 2.6 | 37 | Citations (PDF) |
| 64 | OR27-4 Placebo-Controlled and Open-Label Extension Study of a Novel Hepatic-Targeted Antisense Cimdelirsen (IONIS-GHR-LRx) Under Investigation in Acromegaly Patients | 0.3 | 6 | Citations (PDF) |
| 65 | PMON163 Effect of Osilodrostat on Androgens and Adrenal Hormones in Patients With Cushing's Disease: Long-Term Findings From the Phase III, Prospective LINC 3 Study | 0.3 | 0 | Citations (PDF) |
| 66 | PMON160 Improvements in Clinical Signs of Hypercortisolism and Quality of Life According to Urinary and Late-Night Salivary Cortisol Levels in Patients with Cushing's Disease Treated with Osilodrostat | 0.3 | 0 | Citations (PDF) |
| 67 | PMON66 A Systematic Literature Review to Evaluate Extended Dosing Intervals in the Pharmacological Management of Acromegaly | 0.3 | 0 | Citations (PDF) |
| 68 | A systematic literature review to evaluate extended dosing intervals in the pharmacological management of acromegaly | 2.6 | 11 | Citations (PDF) |
| 69 | Cushing’s syndrome in women: age-related differences in etiology and clinical picture | 2.6 | 7 | Citations (PDF) |
| 70 | EGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas | 4.0 | 66 | Citations (PDF) |
| 71 | Results from ACROCOVID: an international survey on the care of acromegaly during the COVID-19 era | 2.5 | 26 | Citations (PDF) |
| 72 | Glucocorticoid Receptor Antagonism as a New “Remedy” for Insulin Resistance—Not There Yet! | 4.0 | 3 | Citations (PDF) |
| 73 | Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time? | 0.3 | 54 | Citations (PDF) |
| 74 | Thromboembolic disease in hypercortisolism | 2.2 | 10 | Citations (PDF) |
| 75 | Disease and Treatment-Related Burden in Patients With Acromegaly Who Are Biochemically Controlled on Injectable Somatostatin Receptor Ligands | 3.8 | 37 | Citations (PDF) |
| 76 | Cushing’s syndrome Part 2: Advances in Treatment and in Understanding Complications’ Impact | 5.1 | 1 | Citations (PDF) |
| 77 | Pituitary Disorders and COVID-19, Reimagining Care: The Pandemic A Year and Counting | 3.8 | 14 | Citations (PDF) |
| 78 | Levoketoconazole in the Treatment of Patients With Cushing’s Syndrome and Diabetes Mellitus: Results From the SONICS Phase 3 Study | 3.8 | 24 | Citations (PDF) |
| 79 | Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant | 2.5 | 32 | Citations (PDF) |
| 80 | Echocardiographic findings in acromegaly: prevalence of concentric left ventricular remodeling in a large single-center cohort | 2.8 | 13 | Citations (PDF) |
| 81 | A Phase 3 Large International Noninferiority Trial (MPOWERED): Assessing Maintenance of Response to Oral Octreotide Capsules in Comparison to Injectable Somatostatin Receptor Ligands | 0.0 | 0 | Citations (PDF) |
| 82 | Addition of cabergoline to oral octreotide capsules may improve biochemical control in patients with acromegaly who are inadequately controlled with monotherapy | 0.0 | 0 | Citations (PDF) |
| 83 | A Phase 3 Large International Noninferiority Trial (MPOWERED): Assessing Maintenance of Response to Oral Octreotide Capsules in Comparison to Injectable Somatostatin Receptor Ligands | 0.3 | 5 | Citations (PDF) |
| 84 | Osilodrostat is an effective and well-tolerated treatment option for patients with Cushings disease (CD): Final results from the LINC3 study | 0.0 | 1 | Citations (PDF) |
| 85 | Oral octreotide capsules lowered incidence and improved severity of acromegaly symptoms compared to injectable somatostatin receptor ligands—results from the MPOWERED trial | 0.0 | 1 | Citations (PDF) |
| 86 | Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome (LOGICS): Results From a Double-Blind, Placebo-Controlled, Randomized Withdrawal Study | 0.3 | 4 | Citations (PDF) |
| 87 | Safety results from MPOWERED, a phase 3 trial of oral octreotide capsules in adults with acromegaly | 0.0 | 0 | Citations (PDF) |
| 88 | Safety Results From MPOWERED, a Phase 3 Trial of Oral Octreotide Capsules in Adults With Acromegaly | 0.3 | 2 | Citations (PDF) |
| 89 | A double-blind, randomized, placebo-controlled trial of SPI-62 safety and efficacy for the treatment of Cushings syndrome | 0.0 | 2 | Citations (PDF) |
| 90 | Osilodrostat provides sustained control of urinary free cortisol in patients with Cushings disease: final results from a prospective, open-label study (LINC 2) | 0.0 | 0 | Citations (PDF) |
| 91 | Improved acromegaly patient satisfaction with oral octreotide capsules compared with injectable somatostatin receptor ligands in the MPOWERED trial | 0.0 | 1 | Citations (PDF) |
| 92 | Can the follow-up imaging interval for non-functioning pituitary microadenomas be extended? | 0.0 | 0 | Citations (PDF) |
| 93 | Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results | 2.6 | 19 | Citations (PDF) |
| 94 | Levoketoconazole: a novel treatment for endogenous Cushing's syndrome | 2.9 | 14 | Citations (PDF) |
| 95 | Pituitary Society Delphi Survey: An international perspective on endocrine management of patients undergoing transsphenoidal surgery for pituitary adenomas | 2.6 | 18 | Citations (PDF) |
| 96 | Pituitary society expert Delphi consensus: operative workflow in endoscopic transsphenoidal pituitary adenoma resection | 2.6 | 70 | Citations (PDF) |
| 97 | COVID-19 and hypopituitarism | 6.7 | 34 | Citations (PDF) |
| 98 | What to Do with Incidentally Discovered Pituitary Abnormalities? | 3.1 | 12 | Citations (PDF) |
| 99 | Updates in adrenal steroidogenesis inhibitors for Cushing’s syndrome – A practical guide | 5.1 | 49 | Citations (PDF) |
| 100 | Cushing’s syndrome Part 1: Journey to Improving Diagnosis and Outcomes | 5.1 | 0 | Citations (PDF) |
| 101 | Consensus on diagnosis and management of Cushing's disease: a guideline update | 21.7 | 865 | Citations (PDF) |
| 102 | Effects of Pegvisomant and Pasireotide LAR on Vertebral Fractures in Acromegaly Resistant to First-generation SRLs | 4.0 | 57 | Citations (PDF) |
| 103 | A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update | 4.0 | 332 | Citations (PDF) |
| 104 | Fertility and Pregnancy in Women With Hypopituitarism: A Systematic Literature Review | 4.0 | 45 | Citations (PDF) |
| 105 | The tale in evolution: clarity, consistency and consultation, not contradiction and confusion | 2.6 | 22 | Citations (PDF) |
| 106 | Updates in the Medical Treatment of Pituitary Adenomas | 1.8 | 31 | Citations (PDF) |
| 107 | Hypercoagulability in Cushing Syndrome, Prevalence of Thrombotic Events: A Large, Single-Center, Retrospective Study | 0.3 | 60 | Citations (PDF) |
| 108 | Salivary Cortisol in the Diagnosis of Cushing Syndrome, Always More Than One! | 0.3 | 4 | Citations (PDF) |
| 109 | Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase | 21.7 | 208 | Citations (PDF) |
| 110 | A Novel Etiology of Hypophysitis | 3.5 | 21 | Citations (PDF) |
| 111 | Management of patients with persistent or recurrent Cushing’s disease after initial pituitary surgery | 2.9 | 24 | Citations (PDF) |
| 112 | Depression and Impulsivity Self-Assessment Tools to Identify Dopamine Agonist Side Effects in Patients With Pituitary Adenomas | 3.8 | 33 | Citations (PDF) |
| 113 | Cystic appearance on magnetic resonance imaging in bihormonal growth hormone and prolactin tumors in acromegaly | 2.6 | 19 | Citations (PDF) |
| 114 | MON-311 Glucose Metabolism in Acromegaly Patients Resistant to First Generation Somatostatin Receptor Ligands Treated with Pegvisomant And/Or Pasireotide Lar | 0.3 | 0 | Citations (PDF) |
| 115 | Multidisciplinary management of acromegaly: A consensus | 6.7 | 325 | Citations (PDF) |
| 116 | Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide | 4.0 | 90 | Citations (PDF) |
| 117 | MON-332 Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome (LOGICS): A Double-Blind, Placebo-Controlled, Withdrawal Study | 0.3 | 3 | Citations (PDF) |
| 118 | The journey in diagnosis and treatment, from pituitary adenoma to aggressive pituitary tumors | 6.7 | 8 | Citations (PDF) |
| 119 | Pituitary society guidance: pituitary disease management and patient care recommendations during the COVID-19 pandemic—an international perspective | 2.6 | 56 | Citations (PDF) |
| 120 | MON-297 Withdrawal from Long-Acting Somatostatin Receptor Ligand Injections in Adult Patients with Acromegaly: Results from the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study | 0.3 | 0 | Citations (PDF) |
| 121 | Off-Label Use and Misuse of Testosterone, Growth Hormone, Thyroid Hormone, and Adrenal Supplements: Risks and Costs of a Growing Problem | 3.3 | 29 | Citations (PDF) |
| 122 | OR23-07 Results From the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study of Oral Octreotide Capsules in Adult Patients with Acromegaly | 0.3 | 1 | Citations (PDF) |
| 123 | Acromegaly in the elderly patients | 2.5 | 38 | Citations (PDF) |
| 124 | An evaluation of the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ) in adult patients with acromegaly, including correlations with other patient-reported outcome measures: data from two large multicenter international studies | 2.6 | 28 | Citations (PDF) |
| 125 | A Pituitary Society update to acromegaly management guidelines | 2.6 | 299 | Citations (PDF) |
| 126 | Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing’s syndrome | 2.6 | 24 | Citations (PDF) |
| 127 | MON-323 IGF-I Variability and Its Association with Demographic and Clinical Characteristics in Patients with Acromegaly Treated with Injectable Somatostatin Receptor Ligands (SRLS); Results from an International Prospective Phase III Study | 0.3 | 1 | Citations (PDF) |
| 128 | Updates in rare and not-so-rare complications of acromegaly: focus on respiratory function and quality of life in acromegaly | 0.5 | 12 | Citations (PDF) |
| 129 | AcroCOVID: An international survey on care for acromegaly during the COVID-19 era | 0.0 | 3 | Citations (PDF) |
| 130 | Results from the phase 3, randomized, double-blind, placebo-controlled OPTIMAL study of oral octreotide capsules in adult patients with acromegaly | 0.0 | 2 | Citations (PDF) |
| 131 | MON-308 Pituitary Magnetic Resonance Imaging in the Postoperative Follow-Up of Patients with Acromegaly, Less Is More! | 0.3 | 1 | Citations (PDF) |
| 132 | MON-LB55 Biochemical Control of Most Patients Reverting to Injectable Long-Acting Somatostatin Receptor Ligands Is Achieved After One Dose: Results From the Phase 3, Randomized, Double Blind, Placebo-Controlled Optimal Study | 0.3 | 0 | Citations (PDF) |
| 133 | MON-314 Analysis of Adverse Events in Adult Patients with Acromegaly Receiving Oral Octreotide Capsules: Results from the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study | 0.3 | 0 | Citations (PDF) |
| 134 | MON-LB53 Prior Injectable Somatostatin Receptor Ligand Dose Does Not Predict Oral Octreotide Response In The Treatment Of Acromegaly: Results From The Phase 3 OPTIMAL Study | 0.3 | 0 | Citations (PDF) |
| 135 | Biochemical control of most patients reverting to injectable long-acting somatostatin receptor ligands is achieved after one dose: Results from the phase 3, randomized, double blind, placebo-controlled optimal study | 0.0 | 0 | Citations (PDF) |
| 136 | Predictors of response to medical therapy with pegvisomant and pasireotide lar in SRLs-resistant acromegaly | 0.0 | 0 | Citations (PDF) |
| 137 | Impact of imputation method on efficacy results from the phase 3 optimal study of oral octreotide capsules in adult patients with acromegaly | 0.0 | 0 | Citations (PDF) |
| 138 | Analysis of adverse events in adult patients with acromegaly receiving oral octreotide capsules: Results from the phase 3, randomized, double-blind, placebo-controlled optimal study | 0.0 | 0 | Citations (PDF) |
| 139 | Levoketoconazole in the treatment of endogenous Cushing’s syndrome: Extended evaluation phase results of the SONICS study | 0.0 | 2 | Citations (PDF) |
| 140 | Sustained response to treatment with oral octreotide capsules: Results from the phase 3, randomized, double blind, placebo-controlled optimal study | 0.0 | 0 | Citations (PDF) |
| 141 | IGF-I variability and its association with demographic and clinical characteristics in patients with acromegaly treated with injectable somatostatin receptor ligands (SRLs); results from OPTIMAL, an international prospective phase 3 study | 0.0 | 0 | Citations (PDF) |
| 142 | Patients receiving a range of doses of prior injectable somatostatin receptor ligands respond to oral octreotide in the treatment of acromegaly: Results from the phase 3 optimal study | 0.0 | 0 | Citations (PDF) |
| 143 | Durability of response and gender-based analysis from the LINC3 trial of osilodrostat in the treatment in cushing’s disease | 0.0 | 0 | Citations (PDF) |
| 144 | Withdrawal from long-acting somatostatin receptor ligand injections in adult patients with acromegaly: Results from the phase 3, randomized, double-blind, placebo-controlled optimal study | 0.0 | 0 | Citations (PDF) |
| 145 | MON-320 Inter-Rater Reliability of T2 MRI Intensity of Somatotroph Adenomas; Endocrinologists vs. Neuroradiologist Pilot Study | 0.3 | 0 | Citations (PDF) |
| 146 | MON-LB57 Impact of Imputation Method and Response Cutoffs on Results From the Phase 3 OPTIMAL Study of Oral Octreotide Capsules in Adult Patients With Acromegaly | 0.3 | 0 | Citations (PDF) |
| 147 | Safety and Efficacy of Subcutaneous Pasireotide in Patients With Cushing's Disease: Results From an Open-Label, Multicenter, Single-Arm, Multinational, Expanded-Access Study | 3.8 | 18 | Citations (PDF) |
| 148 | Ipilimumab-induced hypophysitis, a single academic center experience | 2.6 | 37 | Citations (PDF) |
| 149 | Functioning Pituitary Adenomas – Current Treatment Options and Emerging Medical Therapies | 2.5 | 57 | Citations (PDF) |
| 150 | Long‐term efficacy and safety of once‐monthly pasireotide in Cushing's disease: A Phase III extension study | 2.3 | 41 | Citations (PDF) |
| 151 | Mifepristone Increases Thyroid Hormone Requirements in Patients With Central Hypothyroidism: A Multicenter Study | 0.3 | 12 | Citations (PDF) |
| 152 | Development of a novel patient-reported measure for acromegaly: the Acro-TSQ | 2.6 | 20 | Citations (PDF) |
| 153 | A tale of pituitary adenomas: to NET or not to NET | 2.6 | 75 | Citations (PDF) |
| 154 | Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial | 21.7 | 94 | Citations (PDF) |
| 155 | Diagnostic utility of Gallium-68-somatostatin receptor PET/CT in ectopic ACTH-secreting tumors: a systematic literature review and single-center clinical experience | 2.6 | 47 | Citations (PDF) |
| 156 | Medical Management of Cushing’s Syndrome: Current and Emerging Treatments | 11.4 | 50 | Citations (PDF) |
| 157 | The Evaluation of Incidentally Discovered Adrenal Masses | 3.3 | 74 | Citations (PDF) |
| 158 | Hypercoagulability and Risk of Venous Thromboembolic Events in Endogenous Cushing's Syndrome: A Systematic Meta-Analysis | 3.8 | 100 | Citations (PDF) |
| 159 | Response to letter to the editor from Professor Jean-François Bonneville | 2.6 | 0 | Citations (PDF) |
| 160 | Hypercortisolemia Recurrence in Cushing's Disease; a Diagnostic Challenge | 3.8 | 40 | Citations (PDF) |
| 161 | Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update | 24.6 | 343 | Citations (PDF) |
| 162 | Magnetic resonance imaging in the management of prolactinomas; a review of the evidence | 2.6 | 39 | Citations (PDF) |
| 163 | OR16-2 Osilodrostat Treatment in Cushing's Disease (CD): Results from a Phase III, Multicenter, Double-Blind, Randomized Withdrawal Study (LINC 3) | 0.3 | 3 | Citations (PDF) |
| 164 | SUN-LB080 ACROSTUDY - Safety and Efficacy of a Cohort of 110 Naïve Patients with Acromegaly Treated with Pegvisomant | 0.3 | 3 | Citations (PDF) |
| 165 | Silent somatotroph pituitary adenomas: an update | 2.6 | 39 | Citations (PDF) |
| 166 | Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial | 21.7 | 156 | Citations (PDF) |
| 167 | Updates in Diagnosis and Treatment of Acromegaly | 2.5 | 61 | Citations (PDF) |
| 168 | Growth hormone deficiency and replacement effect on adult bone mass: A clinical update | 1.0 | 7 | Citations (PDF) |
| 169 | Clinical outcomes in male patients with lactotroph adenomas who required pituitary surgery: a retrospective single center study | 2.6 | 34 | Citations (PDF) |
| 170 | Pituitary-Directed Therapies for Cushing’s Disease | 3.8 | 25 | Citations (PDF) |
| 171 | Physicians’ awareness of gadolinium retention and MRI timing practices in the longitudinal management of pituitary tumors: a “Pituitary Society” survey | 2.6 | 31 | Citations (PDF) |
| 172 | High prevalence of adrenal insufficiency at diagnosis and headache recovery in surgically resected Rathke’s cleft cysts—a large retrospective single center study | 2.5 | 22 | Citations (PDF) |
| 173 | Late-night salivary cortisol (LNSC) levels in a Phase III study of long-acting pasireotide in patients with Cushing's disease (CD) | 0.0 | 2 | Citations (PDF) |
| 174 | An open-label, multicentre, single-arm, expanded-access study of subcutaneous (s.c.) pasireotide in patients with Cushing's disease (CD) | 0.0 | 0 | Citations (PDF) |
| 175 | Update on adrenal insufficiency: diagnosis and management in pregnancy | 2.2 | 38 | Citations (PDF) |
| 176 | Evaluation and Management of Adrenal Insufficiency in Critically ill Patients: Disease State Review | 3.3 | 40 | Citations (PDF) |
| 177 | Clinical profile of silent growth hormone pituitary adenomas; higher recurrence rate compared to silent gonadotroph pituitary tumors, a large single center experience | 2.5 | 40 | Citations (PDF) |
| 178 | Candida Meningitis After Transsphenoidal Surgery: A Single-Institution Case Series and Literature Review | 1.5 | 14 | Citations (PDF) |
| 179 | Stereotactic Radiation Therapy in Pituitary Adenomas, is it Better than Conventional Radiation Therapy | 0.3 | 24 | Citations (PDF) |
| 180 | Medical Therapy with Pasireotide in Recurrent Cushing’s Disease: Experience of Patients Treated for At Least 1 Year at a Single Center | 3.8 | 9 | Citations (PDF) |
| 181 | Recent Progress in the Medical Therapy of Pituitary Tumors | 3.5 | 31 | Citations (PDF) |
| 182 | Predictors of silent corticotroph adenoma recurrence; a large retrospective single center study and systematic literature review | 2.6 | 69 | Citations (PDF) |
| 183 | Pasireotide alone or in combination with cabergoline effectively controls urinary free cortisol levels: results from a prospective study in patients with Cushing's disease (CAPACITY) | 0.0 | 6 | Citations (PDF) |
| 184 | Pasireotide: a novel treatment for patients with acromegaly | 6.9 | 36 | Citations (PDF) |
| 185 | American Association of Clinical Endocrinologists and American College of Endocrinology Disease State Clinical Review: Diagnosis of Recurrence in Cushing Disease | 3.3 | 63 | Citations (PDF) |
| 186 | Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Management of Patients With Nonfunctioning Pituitary Adenomas | 2.0 | 50 | Citations (PDF) |
| 187 | Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline for Pretreatment Endocrine Evaluation of Patients With Nonfunctioning Pituitary Adenomas | 2.0 | 53 | Citations (PDF) |
| 188 | Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Posttreatment Follow-up Evaluation of Patients With Nonfunctioning Pituitary Adenomas | 2.0 | 43 | Citations (PDF) |
| 189 | Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing’s disease: 12-month, Phase III pasireotide study | 2.5 | 30 | Citations (PDF) |
| 190 | Updates on the role of adrenal steroidogenesis inhibitors in Cushing’s syndrome: a focus on novel therapies | 2.6 | 84 | Citations (PDF) |
| 191 | Dopamine agonist therapy induces significant recovery of HPA axis function in prolactinomas independent of tumor size: a large single center experience | 2.5 | 4 | Citations (PDF) |
| 192 | Update on medical treatment for Cushing’s disease | 1.4 | 36 | Citations (PDF) |
| 193 | Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline | 4.0 | 892 | Citations (PDF) |
| 194 | Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study | 2.9 | 74 | Citations (PDF) |
| 195 | Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly | 2.5 | 75 | Citations (PDF) |
| 196 | Safety and tolerability of pasireotide long-acting release in acromegaly—results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study | 2.5 | 50 | Citations (PDF) |
| 197 | The role of combination medical therapy in the treatment of acromegaly | 2.6 | 31 | Citations (PDF) |
| 198 | Longitudinal assessment of response to treatment with oral octreotide capsules in patients with acromegaly: post-hoc analysis of a phase 3 trial | 0.0 | 4 | Citations (PDF) |
| 199 | American Association of Clinical Endocrinologists and American College of Endocrinology Disease State Clinical Review: Management of Acromegaly Patients: What is the Role of Pre-Operative Medical Therapy? | 3.3 | 49 | Citations (PDF) |
| 200 | Medical Treatment of Cushing Disease | 3.5 | 26 | Citations (PDF) |
| 201 | Pituitary-directed medical therapy in Cushing’s disease | 2.6 | 8 | Citations (PDF) |
| 202 | Medical therapy for Cushing’s disease: adrenal steroidogenesis inhibitors and glucocorticoid receptor blockers | 2.6 | 29 | Citations (PDF) |
| 203 | Recovery rate of adrenal function after surgery in patients with acromegaly is higher than in those with non-functioning pituitary tumors: a large single center study | 2.6 | 27 | Citations (PDF) |
| 204 | Preoperative Lateralization Modalities for Cushing Disease: Is Dynamic Magnetic Resonance Imaging or Cavernous Sinus Sampling More Predictive of Intraoperative Findings? | 0.6 | 9 | Citations (PDF) |
| 205 | Fracture risk in adult patients treated with growth hormone replacement therapy for growth hormone deficiency: a prospective observational cohort study | 21.7 | 60 | Citations (PDF) |
| 206 | Discovery of Cushing’s Syndrome After Bariatric Surgery: Multicenter Series of 16 Patients | 2.1 | 20 | Citations (PDF) |
| 207 | Landscape of Familial Isolated and Young-Onset Pituitary Adenomas: Prospective Diagnosis inAIPMutation Carriers | 4.0 | 168 | Citations (PDF) |
| 208 | Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing’s disease | 2.6 | 153 | Citations (PDF) |
| 209 | Metformin-based oral antidiabetic therapy proved effective in hyperglycaemia associated with pasireotide in patients with acromegaly | 0.0 | 5 | Citations (PDF) |
| 210 | Phase III, multicentre, double-blind, randomised withdrawal study of osilodrostat (LCI699) in patients with Cushing's disease: a study design | 0.0 | 0 | Citations (PDF) |
| 211 | Pasireotide long-acting release maintains biochemical control in patients with acromegaly: results from the extension of randomised, Phase III, PAOLA study | 0.0 | 0 | Citations (PDF) |
| 212 | Management of pasireotide-induced hyperglycaemia with proactive monitoring and early intervention: key learnings from the phase III, 24-week PAOLA study | 0.0 | 1 | Citations (PDF) |
| 213 | Challenges and pitfalls in the diagnosis of hyperprolactinemia | 1.4 | 72 | Citations (PDF) |
| 214 | Changes in Plasma ACTH Levels and Corticotroph Tumor Size in Patients With Cushing's Disease During Long-term Treatment With the Glucocorticoid Receptor Antagonist Mifepristone | 4.0 | 87 | Citations (PDF) |
| 215 | Factors Associated with Biochemical Remission after Microscopic Transsphenoidal Surgery for Acromegaly | 0.6 | 60 | Citations (PDF) |
| 216 | LCI699, a Potent 11β-hydroxylase Inhibitor, Normalizes Urinary Cortisol in Patients With Cushing's Disease: Results From a Multicenter, Proof-of-Concept Study | 4.0 | 186 | Citations (PDF) |
| 217 | FRAX score in acromegaly: does it tell the whole story? | 2.3 | 33 | Citations (PDF) |
| 218 | Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial | 21.7 | 381 | Citations (PDF) |
| 219 | Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study | 4.0 | 384 | Citations (PDF) |
| 220 | Polycystic ovarian syndrome and Cushing's syndrome: a persistent diagnostic quandary | 0.9 | 29 | Citations (PDF) |
| 221 | Acromegaly: Assessing the Disorder and Navigating the Therapeutic Options for Treatment | 3.3 | 22 | Citations (PDF) |
| 222 | Case Report: Reversible cabergoline-associated cardiac valvulopathy post drug discontinuation | 0.5 | 3 | Citations (PDF) |
| 223 | Recent advances in the medical treatment of Cushing’s disease | 4.1 | 10 | Citations (PDF) |
| 224 | Effect of pasireotide on GH, IGF1, IGFBP2, IGFBP3, HbA1C and glucose in patients with inadequately controlled acromegaly: exploratory results from a multicentre, randomized, 24-week study (PAOLA) | 0.0 | 2 | Citations (PDF) |
| 225 | Study Design of a Phase II trial of pasireotide s.c. alone or in combination with cabergoline in patients with Cushing's disease | 0.0 | 0 | Citations (PDF) |
| 226 | New avenues in the medical treatment of Cushing’s disease: corticotroph tumor targeted therapy | 2.5 | 28 | Citations (PDF) |
| 227 | Monitoring Patient Improvement Parameters following Pasireotide Treatment in Cushing’s Disease | 0.5 | 7 | Citations (PDF) |
| 228 | A New Era of Cushing Disease Therapeutics | 0.3 | 0 | Citations (PDF) |
| 229 | The role of combination medical therapy in acromegaly | 2.2 | 16 | Citations (PDF) |
| 230 | A New Therapeutic Approach in the Medical Treatment of Cushing’S SYNDROME: GLUCOCORTICOID RECEPTOR BLOCKADE WITH MIFEPRISTONE | 3.3 | 64 | Citations (PDF) |
| 231 | Absence of immunostaining for growth hormone in a subset of patients with acromegaly | 2.6 | 8 | Citations (PDF) |
| 232 | Self-perception of cognitive function among patients with active acromegaly, controlled acromegaly, and non-functional pituitary adenoma: a pilot study | 2.5 | 50 | Citations (PDF) |
| 233 | Can we predict long-term remission after somatostatin analog withdrawal in patients with acromegaly? Results from a multicenter prospective trial | 2.5 | 24 | Citations (PDF) |
| 234 | Extended treatment of Cushing’s disease with pasireotide: results from a 2-year, Phase II study | 2.6 | 47 | Citations (PDF) |
| 235 | Switching patients with acromegaly from octreotide LAR to pasireotide LAR improves biochemical control: crossover extension to a randomized, double-blind, multicenter, Phase III study | 0.0 | 5 | Citations (PDF) |
| 236 | Factors Associated with Biochemical Remission after Open Transsphenoidal Surgery for Acromegaly | 0.6 | 0 | Citations (PDF) |
| 237 | Evaluation of late-night salivary cortisol during a Phase III study with pasireotide in patients with Cushing's disease | 0.0 | 1 | Citations (PDF) |
| 238 | Short-Term Risk of Recurrence of Surgically Treated, Radiotherapy-Naive Pituitary Adenomas | 0.6 | 0 | Citations (PDF) |
| 239 | Medical Management of Persistent and Recurrent Cushing Disease | 1.3 | 31 | Citations (PDF) |
| 240 | Mifepristone, a Glucocorticoid Receptor Antagonist, Produces Clinical and Metabolic Benefits in Patients with Cushing's Syndrome | 4.0 | 474 | Citations (PDF) |
| 241 | Medical management of Cushing’s disease: what is the future? | 2.6 | 85 | Citations (PDF) |
| 242 | Serum IGF-1 In the Diagnosis of Acromegaly and the Profile of Patients with Elevated IGF-1 but Normal Glucose-Suppressed Growth Hormone | 3.3 | 32 | Citations (PDF) |
| 243 | Remission rate after transsphenoidal surgery in patients with pathologically confirmed Cushing’s disease, the role of cortisol, ACTH assessment and immediate reoperation: a large single center experience | 2.6 | 98 | Citations (PDF) |
| 244 | Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience | 2.6 | 145 | Citations (PDF) |
| 245 | Mifepristone: is there a place in the treatment of Cushing’s disease? | 2.5 | 31 | Citations (PDF) |
| 246 | Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly naïve to medical therapy and radiation: what to follow, GH or IGF-1 values? | 2.6 | 41 | Citations (PDF) |
| 247 | Normal Hypothalamic-Pituitary-Adrenal Axis by High-Dose Cosyntropin Testing in Patients with Abnormal Response to Low-Dose Cosyntropin Stimulation: A Retrospective Review | 3.3 | 23 | Citations (PDF) |
| 248 | Cabergoline-Induced Cerebral Spinal Fluid Leak in a Patient With a Large Prolactinoma and MEN1 2010, 20, 198-202 | | 6 | Citations (PDF) |
| 249 | Temozolomide for corticotroph pituitary adenomas refractory to standard therapy | 2.6 | 63 | Citations (PDF) |
| 250 | Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review | 2.6 | 79 | Citations (PDF) |
| 251 | Diabetes Insipidus, Panhypopituitarism, and Severe Mental Status Deterioration in a Patient with Chordoid Glioma: Case Report and Literature Review | 3.3 | 20 | Citations (PDF) |
| 252 | “Relative” adRenal insufficiency in cRitical illness | 3.3 | 14 | Citations (PDF) |
| 253 | Cushing's syndrome might be underappreciated in patients seeking bariatric surgery: a plea for screening | 2.5 | 21 | Citations (PDF) |
| 254 | Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes | 2.6 | 282 | Citations (PDF) |
| 255 | Second-line treatment for Cushing's disease when initial pituitary surgery is unsuccessful | 2.2 | 22 | Citations (PDF) |
| 256 | Successful Treatment of Sulfonylurea-Induced Prolonged Hypoglycemia with Use of Octreotide | 3.3 | 13 | Citations (PDF) |
| 257 | Giant invasive pituitary prolactinoma with falsely low serum prolactin: the significance of ‘hook effect’ | 2.5 | 59 | Citations (PDF) |
| 258 | Failure of successful renal transplant to produce appropriate levels of 1,25-dihydroxyvitamin D | 4.1 | 32 | Citations (PDF) |
| 259 | CAm<sup>2</sup>029 octreotide subcutaneous depot provides stable control of IGF-I and improves key symptoms throughout a 4-week post-dose interval: analysis from the ACROINNOVA 1 trial | 0.0 | 0 | Citations (PDF) |
| 260 | Impact of pasireotide LAR on lipid and glucose metabolism in patients with acromegaly: a systematic review and meta-analysis | 0.0 | 0 | Citations (PDF) |
| 261 | Pituitary incidentaloma: a Pituitary Society international consensus guideline statement | 31.8 | 44 | Citations (PDF) |
| 262 | Impact of pasireotide on lipid and glucose metabolism in patients with acromegaly: a systematic review and meta-analysis | 2.8 | 9 | Citations (PDF) |
| 263 | Development of a Minimum Dataset for the Global Monitoring of the Safety and Efficacy of Growth Hormone Replacement in Adults With Growth Hormone Deficiency (AGHD) | 2.3 | 1 | Citations (PDF) |
| 264 | Natural history of nonfunctioning pituitary microadenomas: a systematic review and individual participant data meta-analysis | 4.0 | 2 | Citations (PDF) |
| 265 | Osilodrostat dose impact on efficacy/safety in Cushing's disease: large, pooled analysis of LINC 2, 3, and 4 | 4.0 | 6 | Citations (PDF) |
| 266 | Osilodrostat-associated Adrenal Gland Shrinkage: A Case Series of Patients With ACTH-dependent Cushing's Syndrome | 4.0 | 10 | Citations (PDF) |
| 267 | Rapid and Sustained Response of Biochemically Uncontrolled Acromegaly to Once-daily Oral Paltusotine Treatment | 4.0 | 12 | Citations (PDF) |
| 268 | Mortality in patients with dopamine agonist-treated hyperprolactinemia: a large matched-cohort study | 2.6 | 2 | Citations (PDF) |
| 269 | Clomiphene Citrate in Men With Hypogonadism—Do we Need to Monitor IGF-1 in All Patients? | 0.3 | 0 | Citations (PDF) |
| 270 | A Novel Evaluation of 24-hour Energy Metabolism in Cushing's Syndrome: The Metabolic Cost of Hypercortisolism | 0.3 | 0 | Citations (PDF) |
| 271 | Patient perceptions of pituitary incidentaloma diagnosis and follow-up: a Pituitary Society international patient survey | 2.6 | 0 | Citations (PDF) |
| 272 | Approach to the Patient with Cushing’s Syndrome: Use of Anticoagulation Therapy | 4.0 | 1 | Citations (PDF) |
| 273 | Efficacy and Safety of Once-Weekly Lonapegsomatropin in Adults With Growth Hormone Deficiency: foresiGHt Trial Results | 4.0 | 3 | Citations (PDF) |
| 274 | Cavernous Sinus Medial Wall Resection: A Retrospective Single-Institution Study on Outcomes in Functional Pituitary Adenomas | 0.6 | 0 | Citations (PDF) |
| 275 | Impact of sex on mortality in patients with pituitary adenomas | 2.6 | 0 | Citations (PDF) |
| 276 | CAM2029 octreotide subcutaneous depot maintains control of IGF-I and symptoms of acromegaly across a 4-week dosing interval and for intervals greater than 28 days: data from the ACROINNOVA 1 trial | 0.0 | 0 | Citations (PDF) |
| 277 | Acromegaly complications: an update | 4.0 | 1 | Citations (PDF) |
| 278 | Age and hematologic parameters can predict prolonged glucocorticoid replacement after remission of cushing disease and adrenal Cushing’s syndrome: A nationwide cohort study | 2.6 | 0 | Citations (PDF) |
| 279 | Increased risk of atrial fibrillation and flutter in patients with Cushing's syndrome: a population-based matched cohort study | 4.0 | 0 | Citations (PDF) |
| 280 | Impact of Osilodrostat on Health‐Related Quality of Life in Cushing's Disease: Analysis of Patient‐Reported Outcomes From the Phase III LINC 3 and LINC 4 Clinical Trials | 2.3 | 0 | Citations (PDF) |
| 281 | Glucagon-like peptide-1 receptor agonist exposure and malignancy risk in patients with endogenous Cushing’s syndrome | 4.0 | 1 | Citations (PDF) |
| 282 | Cancer risk in acromegaly: reassessing the evidence and impact of biochemical control | 4.0 | 0 | Citations (PDF) |
| 283 | Risk of infection-related hospitalization is more than doubled in Cushing’s syndrome vs matched controls | 2.0 | 0 | Citations (PDF) |
| 284 | Consensus on Biomarker Utility for ACTH-Dependent Cushing’s Syndrome: A Pituitary Society Modified Delphi Panel | 4.0 | 0 | Citations (PDF) |
| 285 | Functioning pituitary adenomas in pregnancy: updates and controversies | 2.2 | 0 | Citations (PDF) |
